Malignant Mesothelioma Market
Global Market Study on Malignant Mesothelioma: Cisplatin and Combination Segment Projected to be the Second Most Lucrative Segment by Drug Type
Malignant Mesothelioma Market Segmented By Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine Drugs in Oral, Parenteral Route of Administration
Pemetrexed and combination segment anticipated to grab half the market share of the global malignant mesothelioma market
Pemetrexed and combination segment is the largest segment by drug type in the global malignant mesothelioma market, which is estimated to represent close to US$ 160 Mn, or more than 45% revenue share of the total market in 2017 and more than US$ 300 Mn by the end of the forecast period of 2017–2025, expanding at CAGR of 8.4%.
Pemetrexed and combination segment is expected to gain more than 300 BPS in market share in 2025 over 2017 owing to its better response rate of around 30%-40% when used singly or in combination with other drugs. Pemetrexed and combination drug type segment dominated the global malignant mesothelioma market in terms of revenue in 2016 and the trend is projected to grow throughout the forecast period. Pemetrexed and combination segment is also the most attractive segment, recording a market attractiveness index of 3.2 over the forecast period.
Find Out More about the Report Coverage
- AstraZeneca Plc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Eli Lilly and Company
- Teva Pharmaceuticals
- Boehringer Ingelheim GmbH
- Mylan N.V.
- Fresenius Kabi AG
- Sun Pharmaceuticals Industries Ltd
- Corden Pharma International GmbH
- Concordia International Corp
- Kyowa Hakko Kirin Co Ltd.
- Polaris Pharmaceuticals, Inc.
- MolMed SpA
- Ono Pharmaceutical Co. Ltd
- Nichi-Iko Pharmaceutical Co., Ltd
Increased focus to obtain approvals for efficient combination therapy procedures is one of the significant factors driving revenue growth of the Pemetrexed and combination drug type segment
Most of the companies in the global malignant mesothelioma market are focusing on collaborating with organizations to study the combination of several drugs on malignant mesothelioma. As there are very few companies that have patents for procedures, many companies are conducting clinical trials focusing on different combination drugs.
For instance, in 2017, Boehringer Ingelheim entered into phase 3 for its double-blind, randomized, phase 3 study of Nintedanib in combination with Pemetrexed / Cisplatin followed by continuing Nintedanib monotherapy versus placebo in combination with Pemetrexed / Cisplatin followed by continuing placebo monotherapy for mesothelioma treatment. All these efforts by the key players in the market are boosting the growth of the Pemetrexed and combination segment.
It is assumed that asbestos exposure leads to malignant mesothelioma and given the restrictions on asbestos use globally, it is expected that cases of mesothelioma will reduce in the near future. However, the number of malignant mesothelioma cases do not support these assumptions.
As per statistics released by the Cancer Research UK, 1 in every 140 men and 1 in every 710 women are diagnosed with malignant mesothelioma. It has been observed that there is an increasing trend of malignant mesothelioma cases in men. This particular factor is fuelling the growth in revenue of the Pemetrexed and combination segment.
Evaluation of combination therapies over monotherapy is one of the main factors creating a positive impact on the Pemetrexed and combination drug type segment. Combination therapies such as those using chemotherapy with radio, targeted antibody, cryotherapy, or with other immunotherapies are likely to expand the potential indications for various drugs.
These combination therapies also seek to improve survival rates considerably, as has been evident from limited clinical data in comparison with only surgeries or radiation therapies. Various companies have identified that multiple pathways are affected in tumor regulation and hence seek to use combination therapy as a more effective method.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
The highest CAGR of the Pemetrexed and combination drug type segment is likely to be recorded in the APEJ malignant mesothelioma market
Pemetrexed and combination drug type segment stands the most attractive in the Latin America malignant mesothelioma market, representing a market attractiveness index of 2.7. In the APAC and MEA regional markets, the segment is expected to reach the highest CAGR of 9.5% and 7.5% respectively during the period of forecast.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Route of Administration